Markston International LLC trimmed its position in Celgene Co. (NASDAQ:CELG) by 14.5% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 75,163 shares of the biopharmaceutical company’s stock after selling 12,720 shares during the period. Markston International LLC’s holdings in Celgene were worth $10,960,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CELG. Arcadia Investment Management Corp MI grew its position in Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 400 shares during the period. Thompson Davis & CO. Inc. grew its position in Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the period. Guidant Wealth Advisors acquired a new stake in Celgene during the 3rd quarter worth about $119,000. Motco grew its position in Celgene by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the period. Finally, Balentine LLC grew its position in Celgene by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 481 shares during the period. 79.74% of the stock is currently owned by hedge funds and other institutional investors.

CELG has been the topic of several analyst reports. BMO Capital Markets increased their price target on Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Oppenheimer reaffirmed a “buy” rating and set a $170.00 price target on shares of Celgene in a research report on Friday, October 20th. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target on the stock in a research report on Monday, October 23rd. Cann reaffirmed a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley raised Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have given a buy rating to the stock. Celgene presently has a consensus rating of “Buy” and a consensus target price of $131.18.

Shares of Celgene Co. (NASDAQ:CELG) opened at $106.00 on Friday. Celgene Co. has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The company has a market capitalization of $83,455.60, a PE ratio of 25.18, a PEG ratio of 0.68 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period last year, the firm earned $1.58 EPS. analysts predict that Celgene Co. will post 6.69 earnings per share for the current fiscal year.

WARNING: “Markston International LLC Cuts Position in Celgene Co. (CELG)” was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/markston-international-llc-cuts-position-in-celgene-co-celg/1806732.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.